Free Trial

Avacta Group (AVCTF) Stock Price, News & Analysis

-0.42 (-31.63%)
(As of 07/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
100 shs
Average Volume
3,600 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
AVCTF stock logo

About Avacta Group Stock (OTCMKTS:AVCTF)

Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

AVCTF Stock Price History

AVCTF Stock News Headlines

Avacta Group (OTCMKTS:AVCTF) Trading 50.3% Higher
How did they achieve a perfect track record?
If you want to learn how A Group of traders Made 917 Trades Without A Single Loss! And How You Could Have Consistently Beat the Market by following them...
Avacta Group PLC AVCTF
Avacta Group PLC AVCT
Does this make you sick?
The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.
See More Headlines
Receive AVCTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Not Optionable
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. David Alastair Maclaughlin Smith (Age 58)
    CEO & Executive Director
    Comp: $555.35k
  • Mr. Tony Gardiner (Age 53)
    CFO, Company Secretary & Executive Director
    Comp: $341.46k
  • Dr. Christina Marie Coughlin B.S. (Age 54)
    M.D., Ph.D., Head of Research & Development, Interim Chief Medical Officer and Director
    Comp: $46.28k
  • Ms. Emma Wright
    Group In-House Counsel
  • Mr. Michael Vinegrad
    Group Communications Director
  • Mr. R. Craig Slater FCA (Age 60)
    Chief Operating Officer of Diagnostics
    Comp: $86.3k
  • Dr. Matt Johnson
    Chief Scientific Officer of Diagnostics
  • Dr. Fiona McLaughlin FSB (Age 54)
    Ph.D., Chief Scientific Officer of Therapeutics Division
  • Mr. David Wilson
    Chief Commercial Officer of Diagnostics
  • Ms. Karen Harrison
    Chief Operating Officer of Therapeutics Division

AVCTF Stock Analysis - Frequently Asked Questions

How have AVCTF shares performed this year?

Avacta Group's stock was trading at $1.62 at the beginning of the year. Since then, AVCTF shares have decreased by 44.0% and is now trading at $0.9080.
View the best growth stocks for 2024 here

How do I buy shares of Avacta Group?

Shares of AVCTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:AVCTF) was last updated on 7/14/2024 by Staff

From Our Partners